Another big deal, another sign biotech M&A is back

AbbVie buys Apogee Therapeutics, LSD therapy Phase 3 results, and more biotech news from The Readout research FDA patients Newsletters Log In My Account Subscribe Now My Account Settings Complete your personal information for a more tailored experience Billing Log Out A decade of reporting from the frontiers of health and medicine Newsletters Log In My Account Subscribe Now Biotech Pharma Public Health Health Tech Policy Science First Opinion STAT+ STAT Events Search Log In Try STAT+ My Account Home Newsletter The Readout Another big deal, another sign biotech M&A is back AbbVie buys Apogee Therapeutics, LSD therapy Phase 3…

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning! Pharma companies are on a biotech buying spree, an LSD pill just delivered unusually strong late-stage depression data, and the FDA reverses course of Regenxbio’s treatment.

Also: Today, thousands of industry players (and me!) are gathering in San Diego for BIO to talk deals, science, and whatever comes next. Check out the last item for a jaunt down memory lane about the conference.

Continue to STAT+ to read the full story…